Email Printer Friendly
Oropharynx tumors should be tested for HPV
By DrBicuspid Staff

March 15, 2011 -- Changes in the 2011 National Comprehensive Cancer Network (NCCN) Head and Neck Cancers Guidelines will refine and improve the treatment of these cancers, according to a presentation this week at the NCCN annual conference on Clinical Practice Guidelines and Quality Cancer Care in Hollywood, FL.

One of the main changes is a recommendation that the workup for cancer of the oropharynx include testing of the tumor for human papillomavirus (HPV) p16, according to a story on Medscape.

The incidence of HPV-related oropharyngeal cancer has increased noticeably in recent years, the story noted. In one study, conducted in Sweden, researchers found a progressive proportional increase in HPV detected in biopsies taken to diagnose oropharyngeal cancer, from 23.3% in the 1970s to 29% in the 1980s, 57% in the 1990s, 68% in 2000 to 2002, 77% in 2003 to 2205, and 93% in 2006 and 2007 (International Journal of Cancer, July 15, 2009, Vol. 125:2, pp. 362-366).

HPV-related oropharyngeal cancer appears to be "a new and distinct disease entity and is associated with better survival than non-HPV head and neck cancers," David Pfister, MD, chair of the NCCN Head and Neck Cancers Guidelines Committee, told Medscape.

New HPV test shows promise for head/neck cancer, March 1, 2011

U.K. team details method for evaluating HPV-related oropharyngeal cancer, February 28, 2011

HPV status improves oropharyngeal cancer survival, June 8, 2010

Study could help head/neck cancer patients with HPV, April 30, 2010

Head and neck cancer linked to HPV , October 9, 2009

Copyright © 2011

Last Updated 3/15/2011 11:38:26 AM

Email Printer Friendly

|| Advertising || Building Your Practice || Case Archives || Case Study || Topics || Conferences || Contact Us || Education || Facebook || Forums || Home || Jobs || Links || Mobile || News in Brief || Online CE || Thought Leaders || Privacy Policy || Twitter || Vendor Connect || XML/RSS ||

Copyright © 2014 All Rights Reserved.